|
 |
|
Dear %%=ProperCase(FirstName)=%%, Thank you for your interest in Pharmaceutical Technology's content series on Intranasal Drug Delivery: Identifying Challenges & New Product Opportunities. |
|
| To continue building on what you've learned, we recommend the following article. | |
| Industry Trend: Examining the Emergence of Unit- & Bi-Dose Nasal Sprays Molecules that are limited by a slow onset of action, a suboptimal side–effect profile, or a complicated administration process, may be good candidates for adaptation to a unit– or bi–dose nasal delivery format. This is especially true for drugs targeting the central nervous system (CNS) since this route provides a practical, non–invasive means of bypassing the blood-brain barrier by leveraging the nose– to–brain pathway. Read this article that further explores the advantages and opportunities of adopting unit– and bi–dose nasal delivery technology. 
|
|
|
|
Sponsored by: |
